ANI Pharmaceuticals (BSFA) Stock Statistics & Valuation Metrics
Total Valuation
ANI Pharmaceuticals has a market cap or net worth of EUR 1.48B. The enterprise value is EUR 2.05B.
- Market Cap
- EUR 1.48B
- Enterprise Value
- EUR 2.05B
Share Statistics
ANI Pharmaceuticals has 22,959,488 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 22,959,488
- Owned by Insiders
- 7.75%
- Owned by Institutions
- 1.46%
Financial Efficiency
ANI Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 5.63%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 5.63%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 910.69K
- Profits Per Employee
- 80.76K
- Employee Count
- 970
- Asset Turnover
- 0.61
- Inventory Turnover
- 3.02
Valuation Ratios
The current PE Ratio of ANI Pharmaceuticals is 14.91. ANI Pharmaceuticals’s PEG ratio is 0.01.
- PE Ratio
- 14.91
- PS Ratio
- 1.69
- PB Ratio
- 2.55
- Price to FCF
- 10.37
- Price to Operating Cash Flow
- 8.04
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 883.37M and earned 78.34M in profits. Earnings per share was 3.50.
- Revenue
- 883.37M
- Gross Profit
- 450.64M
- Operating Income
- 81.23M
- Pretax Income
- 95.79M
- Net Income
- 78.34M
- EBITDA
- 207.27M
- Earnings Per Share (EPS)
- 3.50
Cash Flow
In the last 12 months, operating cash flow was 189.47M and capital expenditures -30.02M, giving a free cash flow of 159.44M billion.
- Operating Cash Flow
- 189.47M
- Free Cash Flow
- 159.44M
- Free Cash Flow per Share
- 7.54
Dividends & Yields
ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.65%
- Earnings Yield
- 6.95%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- -17.31%
- 50-Day Moving Average
- 63.70
- 200-Day Moving Average
- 66.79
- Relative Strength Index (RSI)
- 50.51
- Average Volume (3m)
- 243
Important Dates
ANI Pharmaceuticals upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
ANI Pharmaceuticals as a current ratio of 2.71, with Debt / Equity ratio of 60.14%
- Current Ratio
- 2.71
- Quick Ratio
- 2.19
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- 4.05
Taxes
In the past 12 months, ANI Pharmaceuticals has paid 17.45M in taxes.
- Income Tax
- 17.45M
- Effective Tax Rate
- 0.18
Enterprise Valuation
ANI Pharmaceuticals EV to EBITDA ratio is 6.34, with an EV/FCF ratio of 10.18.
- EV to Sales
- 1.66
- EV to EBITDA
- 6.34
- EV to Free Cash Flow
- 10.18
- EV to Operating Cash Flow
- 8.57
Balance Sheet
ANI Pharmaceuticals has EUR 360.21M in cash and marketable securities with EUR 330.34M in debt, giving a net cash position of EUR 29.87M billion.
- Cash & Marketable Securities
- EUR 360.21M
- Total Debt
- EUR 330.34M
- Net Cash
- EUR 29.87M
- Net Cash Per Share
- EUR 1.30
- Tangible Book Value Per Share
- EUR 4.01
Margins
Gross margin is 65.23%, with operating margin of 15.35%, and net profit margin of 10.82%.
- Gross Margin
- 65.23%
- Operating Margin
- 15.35%
- Pretax Margin
- 14.57%
- Net Profit Margin
- 10.82%
- EBITDA Margin
- 26.15%
- EBIT Margin
- 17.38%
Analyst Forecast
The average price target for ANI Pharmaceuticals is EUR 95.73, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 95.73
- Price Target Upside
- 48.42% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- 22.04%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 4
- AI Score
- ―